March 24, 2011 By Robert Graham Reporting ---- Houston Texas at MD Anderson Cancer Research Center -----< Business--Wire>
HyBrid Medical Media ask: What can we do to reduce the Breast Cancer rate in the Black Community
18% of Black Women get Breast Cancer to 7% of White Women, what can we do to reduce the Breast Cancer rate in the Black Community. GenConnect located in Houston at the University of Texas Medical Center research area. Suggested that more research be used using real-time polymerase chain reaction, also called quantitative real time polymerase chain reaction (Q-PCR/qPCR/qrt-PCR) or kinetic polymerase chain reaction (KPCR), is a laboratory technique based on the PCR, which is used to amplify and simultaneously quantify a targeted DNA molecule. A long with Nanoparticles which has the potential to enable breast cancer research and improve molecular imaging, early detection, prevention, and treatment of breast cancer for Black Women. GenConnect offers both absolute and relative quantitation using calibration curves and a choice of normalization strategies. Full validation to ICH guidelines is available to support the analysis of transcript biomarkers as part of a clinical trial.
GenC has new technology to systematically quantify proteins within a small sample by coupling antibody-mediated protein binding with qPCR quantification. The assay probes are target-specific antibodies that are conjugated to two different oligonucleotides through a biotin-streptavidin linkage. When the antibodies bind their target, the oligos come in proximity of each other. Addition of a connector oligonucleotide and DNA ligase creates a DNA amplicon, which is amplified in a qPCR reaction. The qPCR results correlate with the amount of protein in a sample.
Often these are analyzed using immunohistochemistry, but that is much more labor intensive and much less quantitative. Thus, studies now can be conducted with greater ease and throughput with actual tumors. This will allow a better understanding of the protein profiles of cancers, and thus potentially identify new therapeutic biomarkers.
A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.
GenConnect minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.
Using Genomics along with Nanoparticles and real-time polymerase chain reaction in Clinical Trials with Black women we can reduce the cancer rate for black women
March 14, 2011 By Robert Graham Reporting ---- Houston Texas at MD Anderson Cancer Research Center -----< Business--Wire> Over 100 years after the birth of Albert Einstein on March 14, 1879 Breast Cancer has a new friend Nanoparticles.
Nanoparticles has the potential to enable breast cancer research and improve molecular imaging, early detection, prevention, and treatment of breast cancer.
GenConnect scientist say photoluminescent nanoparticles will allow oncologists to discriminate between cancerous cells and healthy cells. Proteomics and bioinformatics will enable researchers to identify markers of Breast cancer susceptibility and precancerous lesions
Numerous investigations have shown that both tissue and cell distribution profiles of anticancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The in vivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also of benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells
Miniaturization will allow the tools for many different tests to be situated together on the same small device. Researchers hope that nanotechnology will allow them to run many diagnostic tests simultaneously.
Nanoparticles nanoshells is use to antibodies that recognize cancer cells. GenConnect scientist envision letting these nanoshells seek out their cancerous targets, then applying near-infrared light. In laboratory cultures, the heat generated by the light-absorbing nanoshells can successfully killed breast cancer tumor cells while leaving neighboring cells intact.
A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer. GenConnect minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.
GenConnect scientists refer to these methods as the top-down approach and the bottom-up approach. The top-down approach involves molding or etching materials into smaller components. This approach has traditionally been used in making parts for computers and electronics. The bottom-up approach involves assembling structures atom-by-atom or molecule-by-molecule, and may prove useful in manufacturing devices used in medicine. Get ready breast cancer science and information technology has breast cancer in the cross hairs
February 25, 2011 By Robert Graham Reporting ---- Washington DC at The National Press Club -----< Business--Wire>
Pre Existing condition Marfan Syndrome is the disease that will benefit the most from what Republicans calls Obama Care
Speaking on what the Republicans Call "Obama Care" and When is the best time to put your hat in the ring for a Presidential Election at The National Press Club Hybrid Pharma ask what dose Mike Huckabee think about Marfan syndrome ?
The Marfan syndrome is a connective tissue disorder. Connective tissue provides substance and support to tendons, ligaments, blood vessel walls, cartilage, heart valves and many other structures.
American Heart Association is concerned about Marfan Syndrome, in the UK Biosensors International develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures.
The BioMatrix™ drug-eluting stent (DES) system was the first to be marketed anywhere in the world to feature an abluminally-coated biodegradable polymer incorporating the anti-restenotic drug Biolimus A9™, specifically developed by Biosensors for use in DES systems. The poly-lactic acid (PLA) polymer fully degrades into carbon dioxide and water over a six to nine month period as the drug elutes, ultimately leaving behind a bare-metal stent (BMS).
The latest version of BioMatrix, the BioMatrix Flex™, launched in Asia, Europe, the Middle East and Africa in May 2010, has the drug and polymer coated on a highly flexible platform designed to enhance deliverability.
Three-year results from the pivotal LEADERS study, presented at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in September 2010, suggested improved safety and efficacy of BioMatrix Flex over Cypher® Select™: there was a diverging trend towards a lower rate of MACE (major adverse cardiac events) in patients treated with BioMatrix Flex versus those treated with Cypher Select when compared to both one and two year results (15.7% vs. 19.0%; P value for superiority = 0.09). In the high-risk sub-group of STEMI (ST Elevation Myocardial Infarction) patients, there was a significant reduction in MACE rate for BioMatrix Flex compared to Cypher Select. Although this was an all-comers study, occurrence of very late stent thrombosis (VLST) events was low: a cumulative 0.2% for BioMatrix Flex out to three years, with no VLST events observed after two years.
BioFreedom™, a ‘next generation’ polymer-free drug-coated stent (DCS), is currently under clinical investigation. It features a micro-structured abluminal surface, which permits the controlled release of Biolimus A9 without the use of a polymer. 12-month results from the First-In-Man (“FIM”) trial were also presented at TCT in September 2010. They demonstrated equivalent efficacy, as measured by late lumen loss, for BioFreedom compared to Taxus® Liberté®, with a trend towards superiority. BioFreedom demonstrated sustained safety up to 12 months, including absence of stent thrombosis.
In the Marfan syndrome, the chemical makeup of the connective tissue isn't normal. As a result, many of these structures are not as stiff as they should be.
Hybrid Pharma Scientist say Marfan syndrome is caused by mutations in the FBN1 gene. FBN1 mutations are associated with a broad continuum of physical features ranging from isolated features of Marfan syndrome to a severe and rapidly progressive form in newborns.
Marfan syndrome is one of the most common inherited disorders of connective tissue. It is an autosomal dominant condition
When the Marfan syndrome has been diagnosed, regular visits with a cardiologist are needed.Chest X-rays and Doppler echo tests are usually performed.
Hybrid Pharma say Marfan syndrome is a clinical diagnosis that is based on family history and the presence of characteristic clinical findings in ocular, skeletal and cardiovascular systems. There are four major clinical diagnostic features:
1. Dilatation or dissection of the aorta at the level of the sinuses of Valsava. 2. Ectopia lentis (dislocated lens of the eye). 3. Lumbosacral dural ectasia determined by CT scan or magnetic resonance imaging (MRI). 4. Four of the eight typical skeletal features.
Genomics is a major criteria for establishing the diagnosis in a family member also include having a parent, child, or sibling who meets major criteria independently, the presence of an FBN-1 mutation known to cause the syndrome, when FBN-1 is inherited by descent and identified in a familial Marfan patient.
The FBN1 gene is the gene associated with the true Marfan syndrome. Genomic Genetic testing of the FBN1 gene identifies 70 - 93 percent of the mutations and is available in clinical laboratories. However patients negative for the test for gene mutation should be considered for evaluation for other conditions that have similar features of Marfan syndrome such as Dietz syndrome, Ehlers Danlos syndrome, and homocystinura. To unequivocally establish the diagnosis in the absence of a family history requires a major manifestation from two systems and involvement of a third system. If a mutation known to cause Marfan syndrome is identified, the diagnosis requires one major criterion and involvement of a second organ system.
Hybrid Parma Panoincell is a new technology that looks for the FBN1 gene.
Hybrid Pharma Panoincell uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.
Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released.
Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.
2011 National Marfan Foundation Grant Program for Researchers with Faculty Appointments
The National Marfan Foundation grant program for researchers with faculty appointments is designed to provide financial support for investigators studying any or all disciplines involved in the Marfan syndrome. Special areas of interest include cardiovascular, genetic, orthopedic and ophthalmologic issues of the Marfan syndrome and related disorders.
The National Marfan Foundation accepts applications on a yearly basis for one- or two-year grants in basic, translational or clinical research. Applications with budgets up to $50,000 per year for a total of $100,000 are acceptable. Grant awards are based on peer review by the NMF Scientific Advisory Board with the approval of the NMF Board of Directors.
February 11, 2011 By Robert Graham Reporting ---- Washington DC at ASM Bio-Defense Research Meeting -----< Business--Wire>
A team of Lab researchers from the Lawrence Livermore National Laboratory (LLNL) may be able to use rare mutations from the virus population of an animal host to distinguish between samples that previously appeared to be genetically identical.
Their work, done in collaboration with a researcher from the Richmond-based California Department of Public Health, won one of three outstanding poster awards at a Defense Threat Reduction Agency (DTRA) conference.
The three poster award winners were selected from among 588 posters that were presented at DTRA's Chemical & Biological Science & Technology Conference held recently in Orlando, Fla.
Information from the scientists' work could potentially be useful for forensic purposes, as well as determining the likelihood that a virus may jump from one species of animal to another, or from animals to human beings.
The Lab team is led by Monica Borucki, a biomedical scientist in Physical & Life Sciences, and includes Jonathan Allen and Clinton Torres, both bioinformatics scientists from Computation, and Tom Slezak, the associate Informatics program leader from Global Security. They are collaborating with Sharon Messenger of the California Department of Public Health.
"Understanding the evolution of RNA viruses is a major scientific problem that is essential for developing a better biodefense," Borucki said.
Backing up her point, Borucki noted that three-quarters of recently discovered pathogens are viral, that one to four new pathogenic viruses are discovered each year and that most of the viruses that jump to new species are viruses with genomes composed of RNA. Most of these viruses are animal viruses that "jump species" and infect humans.
At the DTRA conference, Allen presented data from preliminary experiments that involved ultra-deep Illumina sequencing on three different naturally infected samples --brain tissue from two rabid foxes that appear to be involved in a rabies host-jumping event and a nasal sample from a calf infected with bovine coronavirus.
Through the California Department of Public Health, Livermore scientists have received brain tissue samples of foxes that have apparently been bit by skunks, contracted rabies and attacked people or pets. In 2009, there was a 356 percent increase in the number of foxes contracting rabies in California, with most of these cases occurring in Humboldt County.
The Laboratory researchers have theorized that as the rabies have jumped from skunks to foxes the genes of the rabies virus have undergone changes.
"We're interested in understanding how a virus changes at the population level as it adapts from one host to another," Borucki said. "We're particularly interested in this area because many diseases move from animals to people."
The researchers' ultimate goal is to determine the probability of a specific animal virus jumping from animals to humans, Borucki noted.
While many research teams conduct genomic analysis on about 300 base pairs of the 12,000-base pair rabies genome, the LLNL team has performed this analysis on 11,000 base pairs. In addition, normally 1-30 viral genome copies are used in analysis, but the Lab team relied on some 300,000 viral genome copies.
"Although the rabies virus has jumped species multiple times in the past, the event is relatively rare and whole genomic sequencing analysis has never been applied to such an event," Borucki said.
During the next year, the team plans to analyze 50 different rabies samples from a naturally occurring host-jumping event (skunks to foxes in Northern California) and 35 different bovine coronavirus samples from a laboratory-simulated host-jumping event. This work is funded by the Defense Threat Reduction Agency as part of the Transformational Medical Technologies program.
Hybrid Pharma Panoincell uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.
Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released.
Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.
February 5, 2011 By Robert Graham Reporting ---- Dallas Texas NFL Super Bowl Weekend -----< Business--Wire> Breast cancer is the most commonly diagnosed cancer in women worldwide. Targeted therapies for treating breast cancer have helped to reduce the death rate, according to results from Hybrid Pharmaceutical clinical studies.
Approximately 30% of malignant breast cancers demonstrate overamplification of the human epidermal receptor type 2 (HER2) gene. HER-2 can be resistant to low-doses of anthracycline-based chemotherapy.
The Good News is that science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array. The better News is that Genomics is on the Clock.
Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Hybrid Pharma Semiconductor Sequencing. "Quantum Theory" In Action for Breast Cancer Patients.
A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA or RNA template in the processes of replication and transcription. In association with a Hybrid Pharma Panoincell qX also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection and Analysis for Breast Cancer model after McCulloch-Pitts. Panoincell qX computer-assisted diagnosing of breast cancer from mammograms. How Panoincell qX works is a genetic network simulation trained with tumor incidence data from knockout experiments.
Hybrid Pharma Panoincell uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.
Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released.
Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.
HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients.
January 30, 2010 By Robert Graham ---- Phacilitate’s 7th annual Cell & Gene Therapy Forum in Washington DC
While Attending Phacilitate’s 7th annual Cell & Gene Therapy Forum in Washington DC Hybrid Medical Media came up with the New Slogan for Global Alliance for Vaccine & Immunization (GAVI) "Committed to Our Mission with Analytics" Soon After
Bill Gates and ABU DHABI, UNITED ARAB EMIRATES on - January 25, 2011: HH General Sheikh Mohammed bin Zayed Al Nahyan Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces (right) receives Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation, at the Al Bateen Palace. (Philip Cheung / Crown Prince Court - Abu Dhabi). US$ 66 million donation from the Crown Prince of Abu Dhabi and the Bill & Melinda Gates Foundation for children in Afghanistan
Geneva, 26 January 2011 — A new partnership marking broader global collaboration around vaccines injects needed funding into the GAVI Alliance’s efforts to help save millions of children and hopefully inspires other philanthropists to invest in childhood immunisation programmes. Private donations like this send a clear signal to our government donors that they are not alone in seeing the value of immunisation. Dagfinn Høybråten, Chair of the GAVI Alliance board
Announced in Abu Dhabi on Wednesday, His Highness Sheikh Mohamed bin Zayed Al Nahyan, the Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, and the Bill & Melinda Gates Foundation entered into a partnership in which each committed US$ 50 million for immunisation programmes in Afghanistan and Pakistan.
Of the total US$ 100 million, the Global Alliance for Vaccines and Immunisation (GAVI), will receive US$ 66 million to buy and deliver additional supplies of the five-in-one pentavalent vaccine and to support the introduction of new pneumococcal vaccines in Afghanistan. These vaccines help protect children from the main killers of children under five, including pneumonia, diphtheria, pertussis (whooping cough), tetanus, hepatitis B, Haemophilus influenzae type B (HiB), which causes meningitis.
“Private donations like this send a clear signal to our government donors that they are not alone in seeing the value of immunisation. If we are to fulfill our promise to all children, the GAVI Alliance needs to raise an extra US$ 3.7 billion for immunisation in the run up to 2015. We hope this commitment will inspire all concerned to invest even more to save and protect young lives,” said Dagfinn Høybråten, Chair of the GAVI Alliance board.
Backed by the Bill & Melinda Gates Foundation and an increasing number of sovereign governments since its launch in 2000, the GAVI Alliance has succeeded in immunising more than 288 million children, preventing more than five million premature deaths, according to WHO figures.
If fully funded, the GAVI Alliance will be able to immunise an additional 230 million children with pentavalent vaccine by 2015, and protect 90 million children with new pneumococcal vaccines which are already being introduced in the first of more than 40 developing countries. GAVI also plans to introduce vaccines against rotavirus in 33 countries.
The bulk of GAVI’s funds come from 16 sovereign governments and the Bill & Melinda Gates Foundation. The GAVI Campaign works to secure funds from private donors and other partners, including Spain’s "la Caixa" Foundation.
“I sincerely hope that other potential donors will recognise this inspired investment as a call to action,” said Paul O’Connell, Chairman of the Campaign. “If you want to provide children with a healthy start in life and enable them to grow up to build strong communities, then immunisation is one of the most cost-effective and proven ways to do it,” he said.
# # #
The GAVI Alliance is a Geneva-based public-private partnership aimed at improving health in the world’s poorest countries. The Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry in both industrialised and developing countries, research and technical agencies, civil society, the Bill & Melinda Gates Foundation and other private philanthropists.
In 2007, the Alliance launched the GAVI Campaign, a U.S. 501(c )(3) public charity fostering robust private sector engagement in support of vaccine programmes in the developing world. For more information on giving opportunities for individuals, foundations, and corporations, please visit
January 15, 2010 By Robert Graham ---- Frontiers in Personalized Medicine: Washington DC
How President Obama and Congress helping find a Breast Cancer Cure.
Genomics Science for Breast Cancer is making real progress with the Science Communities. President Obama 111th Congress Passing H.R.5116 COMPETES Act "America COMPETES Re authorization Act of 2010" and Stand Up to Cancer $15 million grant will help The Science Community Develop A blood test so sensitive that it can spot a single cancer cell lurking among a billion healthy ones is moving one step closer to being available at your doctor's office. A example of this technology:
Hybrid Pharma Panoincell uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together.Hybrid'schips are designed like any other semiconductor chips.
Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released.
Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.
When a nucleotide, is added to a DNA template and is then incorporated into a strand of DNA, a hydrogen ion will be released. The charge from that ion will change the pH of the solution, which can be detected. Hybrid's sequencer—essentially will call the base, going directly from Biochemical information to digital information. The out come is to find the p53, p63 and p73 genes that make up Breast Cancer
Mass General, Sloan-Kettering, University of Texas M.D. Anderson Cancer Center in Houston and Dana-Farber Cancer Institute in Boston will start using the test this year. They are one of the "dream teams" sharing a $15 million grant from the Stand Up to Cancer telethon, run by the American Association for Cancer Research.
H.R.5116 COMPETES Act bioscience research program will support Breast Cancer research and development of standard reference materials, measurements, methods, and genomic and other data to advance— ‘‘(1) biological drug research and development; ‘‘(2) molecular diagnostics; ‘‘(3) medical imaging technologies; and ‘‘(4) personalized medicine.
Fund the creation of bioscience user facility to provide access to advanced or unique equipment, services, materials, and other resources to industry, institutions of higher education, nonprofit organizations, and government agencies to perform research and testing.
Fund POSTDOCTORAL FELLOWS to the extent practicable, assign 1 or more fellows from the postdoctoral fellowship program established in section 19 to the bioscience research program and much much more.
2011 is going to be a Great Year for Breast Cancer.
